Brean Murray Carret & Company

Brean Murray Carret & Company has raised the price target on Inhibitex (NASDAQ: INHX) from $19 to $26 after the company announced its plans to have all outstanding shares acquired by Bristol-Myers Squibb (NYSE: BMY) for $26/share. Buy rating is maintained on INHX.

Brean Murray Carret & Company has downgraded Abercrombie & Fitch (NYSE: ANF) from Buy to Hold and has removed its $70 price target.

Brean Murray Carret & Co reiterates its Hold rating on Onyx Pharmaceuticals (NASDAQ: ONXX) as prior takeout pessimism offsets impressive frontline Carflizomib results. BMC says, “Results for the 53 patient Phase ½ trial of carfilzomib (CFZ) in combination with lenalidomide and low-dose...

Brean Murray Carret & Co reiterates its Buy rating and $10 target price on Xerox (NYSE: XRX) as the company is seen as solidly positioned for 2012. BMC says, “We continue to believe XRX is better positioned heading into 2012 than the stock would suggest. And after our meetings [with management...

Brean Murray Carret & Company has published a research report on BioMarin Pharmaceuticals (NASDAQ: BMRN) commenting on the company's Analyst Day highlights. In the report, Brean Murray writes, "Morquio syndrome affects 1/200,000 children (about 1,500 in the U.S.) and is the subject of BioMarin...

Brean Murray Carret & Company has downgraded THG (NASDAQ: THQI) from Buy to Hold and has removed its $4.50 price target.

Brean Murray Carret & Company has initiated coverage on PDC Energy (NASDAQ: PETD) with a Buy rating and $46 price target.

Brean Murray Carret & Company has lowered the price target on Regeneron Pharmaceuticals (NASDAQ: REGN) from $78 to $67 and maintains its Buy rating.

A report from Brean Murray Carret & Co. reiterates its Buy rating and lowers its price target from $11 to $8 on Isle of Capri Casinos (NASDAQ: ISLE). The report states, “While properties impacted by flooding on Mississippi continued to disappoint, recent property enhancements, improved...

A report from Brean Murray Carret & Co reiterates its Buy rating and lowers its price target from $29 to $28 on Electronic Arts (NASDAQ: ERTS). The report states, “EA announced the acquisition of a small social game developer called KlickNation yesterday. KlickNation will be folded into...

A report from Brean Murray Carret & Co reiterates its Buy rating and $85 price target, and raises its FY12/13 EPS estimates from $5.09/$5.79 to $5.26/$5.90 on PVH Corp. (NYSE: PVH). The report states, “We remain impressed with the company's ability to leverage the strong global performance of...

A report from Brean Murray Carret & Co reiterates its Buy rating and raises its price target from $26 to $29 on Express (NYSE: EXPR). The report states, “Express continues to trump this uncertain economic environment by offering the quality and fashion consumers are demanding and by enhancing...

Brean Murray has raised the price target on Inhibitex (NASDAQ: INHX) from $12 to $19 and maintains its Buy rating.

A report from Brean Murray Carret & Co reiterates its Buy rating and raises its price target from $28 to $31 on Western Digital (NYSE: WDC). The report states, “We remain bullish on WDC, although we can't have complete visibility on 2012 / 2013 earnings power until we're certain what part of...

Brean Murray Carret & Co maintains its Buy rating on Seagate Technology PLC (NASDAQ: STX) and increases its price target to $23 from $18 on pricing that was stronger than expected. According to BMC, “Due to stronger than anticipated pricing, STX provided updated guidance suggesting Dec Q EPS...